Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 7, 2017 PPLT, OMER, ATHN, TDC, PPHM, PAM Are Seasonally Ripe To Go Down In the Next Five Weeks
March 7, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of ETFS Platinum Trust (NYSE:PPLT), Omeros Corporation (NASDAQ:OMER), athenahealth, Inc. (NASDAQ:ATHN), Teradata Corporation (NYSE:TDC), Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Pampa Energa S.A. (NYSE:PAM) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
The following stocks are expected to go Down:
Symbol Company Expected Return Odds By The Following Date PPLT ETFS Platinum Trust -2.27% 100.00% (7 of 7) Thursday, March 23rd 2017 OMER Omeros Corporation -15.26% 85.71% (6 of 7) Tuesday, April 18th 2017 ATHN athenahealth, Inc. -4.49% 88.89% (8 of 9) Monday, April 3rd 2017 TDC Teradata Corporation -1.85% 88.89% (8 of 9) Thursday, March 9th 2017 PPHM Peregrine Pharmaceuticals Inc. -9.42% 85.00% (17 of 20) Friday, March 10th 2017 PAM Pampa Energa S.A. -2.97% 85.71% (6 of 7) Thursday, March 9th 2017ETFS Platinum Trust (NYSE:PPLT) - ETFS Physical Platinum.
Omeros Corporation (NASDAQ:OMER) - Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets OMIDRIA for use during cataract surgery or intraocular lens replacement. The company s clinical products include OMS721 that is in Phase III clinical trials for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trials for the treatment of thrombotic microangiopathies, IgA nephropathy, and other renal diseases. Its clinical programs also comprise OMS824, which is in Phase II clinical trials for the treatment of schizophrenia and Huntington's diseases; OMS405 that is in Phase II clinical trials for the treatment of opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trials for use during urological procedures. The company s preclinical programs include OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 to control surgical and traumatic bleeding; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Its preclinical programs also comprise GPR17 for the treatment of demyelinating disorders; GPR101 for appetite and eating disorders; GPR151 for the treatment of neuropathic pain and cognition; GPR161 for triple-negative breast cancer treatment; GPR174 for dysfunction of regulatory T-cell modulation; GPR183 for the treatment of osteoporosis and EBV-related diseases; and GPCR and Antibody Platform for CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trials for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington..
athenahealth, Inc. (NASDAQ:ATHN) - athenahealth, Inc., together with its subsidiaries, provides network-based medical record, revenue cycle, patient engagement, care coordination, and population health services for medical groups and health systems. It offers athenaCollector, a network-enabled billing and practice management solution; athenaClinicals, an electronic health record for electronic health record management to help manage patient s clinical documentation; athenaCommunicator, an engagement and communication solution that provides an automated communication service between patients and provider practices for interactions outside the exam room; and athenaCoordinator for order transmission and care coordination services. The company also provides athenahealth Population Health, a cloud-based population health service; and Epocrates service that include clinical information and decision support services in the areas of drug and disease information, medical calculator and tools, clinical guidelines, clinical messaging, and market research. In addition, it offers athenahealth Health Plan data exchange facilitates to exchange the data between providers and health plans for the healthcare operations of clients; athenaOne Analytics that includes an analytics and dashboard application, as well as provides visibility into the financial and operational health of an organization; and pre-certification processing and referral processing services. The company serves clients in the health care industry through its direct sales force and channel partners in the United States and internationally. athenahealth, Inc. was formerly known as athenahealth.com, Inc. and changed its name to athenahealth, Inc. in November 2000. The company was founded in 1997 and is headquartered in Watertown, Massachusetts..
Teradata Corporation (NYSE:TDC) - Teradata Corporation provides analytic data solutions and related services in the United States and internationally. The company operates through Americas Data and Analytics, and International Data and Analytics segments. Its analytic data solutions comprise software, hardware, and related business consulting and support services for data warehousing, big data, and tools for data integration, data discovery, and business intelligence. The company offers hybrid cloud solutions, including Teradata Software sold on public clouds and Teradata managed cloud solutions. It also provides business analytics solutions comprising analytic business consulting, and IP capture and management. In addition, the company offers ecosystem architecture consulting, which enables customers to build an analytical ecosystem independent of technology, leveraging Teradata, open source, and other commercial solutions; and customer support services, such as installation, maintenance, monitoring, back-up, and recovery services. It serves various industries comprising banking/financial services, communications, energy, government, insurance and healthcare, manufacturing, oil and gas, retail, travel and transportation logistics, and utilities. The company has strategic partnerships with Accenture Limited, Capgemini Group, Cognizant Technology Solutions Corporation, Deloitte LLP, International Business Machines Corporation, and Wipro Limited. Teradata Corporation was founded in 1979 and is headquartered in Dayton, Ohio..
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. It s lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; Merck KGaA; and National Comprehensive Cancer Network, as well as collaboration agreement with AstraZeneca PLC and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California..
Pampa Energa S.A. (NYSE:PAM) - Pampa Energ a S.A., an integrated electricity company, through its subsidiaries, engages in the generation, transmission, and distribution of electricity in Argentina. The company operates hydroelectric and thermal generation facilities. It has an installed generating capacity of 2,217 MW. The company operates and maintains high-tension transmission network of 12,365 km of lines of its own in Argentina, as well as 6,158 km of Transba high voltage lines in the Province of Buenos Aires; and distributes electricity to approximately 2.8 million customers. It is also involved in the exploration and exploitation of oil and gas; operation of financial investment, as well as investing in other companies with complementary businesses; and authorization in acting as an agent and clearing member of ROFEX. The company was formerly known as Pampa Holding S.A. and changed its name to Pampa Energ a S.A. in September 2008. Pampa Energ a S.A. was founded in 1945 and is based in Buenos Aires, Argentina..
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com